Cobenfy (Xanomeline Tart/Trospium Chlor) Patent Expiration, LOE Window & CMS Spending
Cobenfy (Xanomeline Tart/Trospium Chlor) by Bristol Myers Squibb: FDA Orange Book LOE 2039-10-29, 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and $3,145 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N216158 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2039-10-29 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.8M |
| 2024 Medicare Part D Spend | $2.4M |
| 2024 Medicaid Spend | $1.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,145 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.